The difference in the efficiency towards the different CD30+ cell lines might be due to the various anti-tumor mechanisms, such as effector to target-cell contact, signaling and tumor apoptosis via the Fas ligand of CIK cells, which might be not as effective for each cell line [6,9,14,15]. The gene discussed is FASLG; the disease is neoplasm.